A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Dr. Reddy’s Laboratories, Servier, and AstraZeneca. Highlights below.  

For the latest news roundup on small and Emerging Pharma companies, see Biotech Briefs. 

Mfg News 
* Dr. Reddy’s Pauses Shipments of Generic Version of Diabetes Drug Semaglutide 
Mergers and Acquisitions 
* Servier Completes $2.6-Bn Deal for Edgewise Therapeutics’ Muscular Dystrophy Biz 
Partnering News 
* AstraZeneca, China’s Dizal Pharmaceutical in $1.5-Bn Licensing Pact for Lung Cancer Drug

---

Mfg News 

Dr. Reddy’s Pauses Shipments of Generic Version of Diabetes Drug Semaglutide 
Dr. Reddy’s Laboratories has paused its shipments of its generic version of semaglutide injection for treating Type II diabetes due to an issue associated with the active pharmaceutical ingredient. The company said that certain batches of semaglutide were found to be out of specification.  

Dr. Reddy’s had launched its biosimilar of semalglutide in India in March 2026 under the brand name Obeda and in Canada in May 2026. The company has stated that until the issue is resolved, commercial supplies of the product will be delayed for a certain period of time. 

Source: Dr. Reddy’s 

---

Servier Completes $2.6-Bn Deal for Edgewise Therapeutics’ Muscular Dystrophy Biz 
Servier, a French bio/pharmaceutical company, has completed its acquisition of the muscular dystrophy business of Edgewise Therapeutics, a bio/pharmaceutical company focused on serious muscle disorders, for up to $2.65 billion ($1.55 billion upfront and $1.1 billion in milestone payments).  

The acquisition advances Servier’s rare neurology pipeline with a late-stage asset, sevasemten, an investigational orally administered myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with rare muscular dystrophy. Sevasemten is currently being investigated for Becker muscular dystrophy and is in Phase II development for treating Duchenne muscular dystrophy. The acquisition also provides Servier with additional capabilities by integrating Edgewise Therapeutics’ expertise to advance the development of sevasemten. 

In 2024, Servier made the strategic decision to focus on rare neurology as its next growth driver and become a global player by 2030. Since then, the company has been targeting rare neurological disorders, including refractory epilepsy, genetically driven autism spectrum disorders, movement disorders, and neuromuscular diseases.   

Source: Servier 

---

Partnering News 

AstraZeneca, China’s Dizal Pharmaceutical in $1.5-Bn Licensing Pact for Lung Cancer Drug 
AstraZeneca has entered an exclusive license agreement with Dizal Pharmaceutical, a Shanghai-based bio/pharmaceutical company, for Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer, in a deal worth up to $1.5 billion ($600 million upfront and $900 million in milestone payments).  

AstraZeneca will acquire worldwide rights to develop and commercialize Zegfrovy. Zegfrovy is approved in the US and China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. 

AstraZeneca will make an upfront payment to Dizal of $600 million and additional payments of up to $900 million upon achievement of specific development, regulatory, and sales-related milestones. Additionally, Dizal will receive tiered royalties on the global sales of Zegfrovy. 

The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances.  

Source: AstraZeneca